|
|
Drugs for Heavy Chain Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB): (show top 50)
(show all 127)
| id | | Name | Status | Phase | Clinical Trials | Cas Number | PubChem Id |
|---|
| 1 | | Metoprolol | approved, investigational | Phase 4 | 201 | 37350-58-6, 51384-51-1 | 4171 | (+/-)-Metoprolol (RS)-Metoprolol 1-(Isopropylamino)-3-(4-(2-methoxyethyl)phenoxy)propan-2-ol 1-(Isopropylamino)-3-(p-(2-methoxyethyl)phenoxy)-2-propanol 1-(isopropylamino)-3-[4-(2-methoxyethyl)phenoxy]propan-2-ol 1-[(1-methylethyl)amino]-3-({4-[2-(methyloxy)ethyl]phenyl}oxy)propan-2-ol 1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol 1-[4-(2-methoxyethyl)phenoxy]-3-propan-2-ylamino-propan-2-ol 3-[4-(2-methoxyethyl)phenoxy]-1-(propan-2-ylamino)propan-2-ol 37350-58-6 51384-51-1 54163-88-1 AB00053499 AC-19022 AC1L1HKM AstraZeneca Brand of Metaoprolol Tartrate AstraZeneca Brand of Seloken BRD-A03623303-045-02-0 Beatrolol Beloc Beloc Duriles Beloc-Duriles BelocDuriles Betaloc Betaloc Astra Betaloc-Astra BetalocAstra Betalok C07202 CCRIS 4198 CGP 2175 CGP-2175 CGP2175 CHEBI:6904 CHEMBL13 CID4171 D008790 D02358 DB00264 DL-metoprolol Dl-Metoprolol Dutoprol EINECS 253-483-7 EINECS 257-166-4 H 93 26 H 93-26 H 9326 | HMS2090B15 HSDB 6531 I01-7125 I06-0125 Jsp006606 L000669 LOPRESSIDONE LS-122450 Leiras Brand of Metoprolol Succinate or Metoprolol Tartrate Lopresor Lopresoretic Lopressor Lopressor HCT Meijoprolol Metohexal Metoprolol Metoprolol (USAN/INN) Metoprolol Tartrate Metoprolol [USAN:INN:BAN] Metoprolol slow release Metoprolol succinate Metoprolol tartrate Metoprololum Metoprololum [INN-Latin] Metroprolol MolPort-005-938-039 NCGC00021148-02 NCGC00021148-03 NCGC00021148-04 Novartis Brand of Metprolol Tartrate Preblok Prelis Presolol Selo-Zok Seloken Seloken AstraZeneca Brand Selopral Seroken Spesicor Spesikor TOPROL-XL Tartrate, Metoprolol Toprol Toprol XL Toprol-XL UNII-GEB06NHM23 dl-Metoprolol metoprolol | |
| | 2 | | Doxazosin | approved | Phase 4 | 57 | 74191-85-8 | 3157 | 1-(4-Amino-6,7-Dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl)piperazin 1-(4-Amino-6,7-dimethoxy-2-chinazolinyl)-4-(2,3-dihydro-1,4-benzodioxixin-2-ylcarbonyl)piperazin 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-[4-(1,4-benzodioxan-2-yl)carpiperazin-1-yl)]-6,7-dimethoxyquinazoline mesylate 2-[4-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)piperazin-1-yl]-6,7-bis(methyloxy)quinazolin-4-amine 2-[4-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine 2-{4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]piperazin-1-yl}-6,7-dimethoxyquinazolin-4-amine 74191-85-8 77883-43-3 (mesylate) AC-11062 AC1L1FAT AC1Q470P AC1Q4EXN AKOS001681453 BPBio1_000963 BRD-A13188892-066-03-3 BSPBio_000875 C06970 C23H25N5O5 CHEBI:4708 CHEMBL707 CID3157 CPD000097306 Cardura XL (TN) Cardura-1 Cardura-2 Cardura-4 ChemDiv2_005017 D07874 D9815_SIGMA DB00590 | Doxazosin (INN) Doxazosin [INN:BAN] Doxazosin mesilate Doxazosina Doxazosina [Spanish] Doxazosine Doxazosine [French] Doxazosinum Doxazosinum [Latin] HMS1383E01 HMS2090C20 I06-1346 IDI1_003732 L000738 LS-110228 Lopac0_000474 MolPort-001-684-491 NCGC00018158-06 NCGC00089775-02 Normothen Oprea1_259518 Prestwick0_000858 Prestwick1_000858 Prestwick2_000858 Prestwick3_000858 SAM002589981 SPBio_002796 UK 33274 UK-33274 UNII-NW1291F1W8 [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(2,3-dihydro-1,4-benzodioxin-3-yl)methanone doxazosin |
| | 3 | | Carvedilol | approved, investigational | Phase 4 | 163 | 72956-09-3 | 2585 | (+-)-1-(Carbazol-4-yloxy)-3-((2-(O-methoxyphenoxy)ethyl)amino)-2-propanol (+-)-1-(Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol (+-)-1-Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol (+/-)-1-(Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol 1-(9H-Carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol 1-(9H-carbazol-4-yloxy)-3-[(2-{[2-(methyloxy)phenyl]oxy}ethyl)amino]propan-2-ol 1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol 1-(9H-carbazol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol 107741-96-8 72956-09-3 AB1004830 AC-1641 AC1L1E0B Artist Artist (TN) Atlana Pharma brand of carvedilol BM 14190 BM-14-190 BM-14.190 BM-14190 BRD-A10977446-001-04-8 BRD-A10977446-045-01-1 Bio-0014 C043211 C06875 C2260 C24H26N2O4 CHEBI:3441 CHEMBL723 CID2585 CPD000449280 Carvedilol Carvedilol (JAN/USAN/INN) Carvedilol [USAN:INN:BAN:JAN] Carvedilolum Carvedilolum [Latin] Coreg Coreg (TN) Coreg CR Coropres Coropress D00255 DB01136 DQ 2466 DQ-2466 Dibloc | Dilatrend EG-P042 Eucardic GlaxoSmithKline brand of carvedilol HMS2051N03 HMS2089B09 HMS2093E12 HSDB 7044 I06-0064 I06-1477 KBio2_002145 KBio2_004713 KBio2_007281 KBio3_002323 KBioGR_001252 KBioSS_002145 Kredex L001243 LS-121875 Lakeside brand of carvedilol MLS000758299 MLS000759508 MLS001424092 MolPort-003-666-814 NCGC00167832-01 NCGC00167832-02 NCGC00167832-03 Querto Roche brand of carvedilol SAM001246736 SAM001247021 SK&F-105517 SKF 105517 SMR000449280 SPBio_001885 STK621453 Spectrum2_001673 Spectrum3_001182 Spectrum4_000636 Spectrum5_001436 Spectrum_001665 TL8005080 UNII-0K47UL67F2 carvedilol carvedilol, (+-)-isomer carvedilol, (R)-isomer carvedilol, (S)-isomer carvedilol, 14C-labeled |
| | 4 | | Neurotransmitter Agents | | Phase 4 | 17734 | | | | 5 | | Peripheral Nervous System Agents | | Phase 4, Phase 3, Phase 1, Phase 2 | 22776 | | | | 6 | | Adrenergic Agents | | Phase 4 | 5140 | | | | 7 | | Vasodilator Agents | | Phase 4 | 3438 | | | | 8 | | Autonomic Agents | | Phase 4, Phase 3, Phase 1, Phase 2 | 9774 | | | | 9 | | Sympatholytics | | Phase 4 | 555 | | | | 10 | | Adrenergic alpha-1 Receptor Antagonists | | Phase 4 | 470 | | | | 11 | | Antihypertensive Agents | | Phase 4 | 4095 | | | | 12 | | Adrenergic alpha-Antagonists | | Phase 4 | 727 | | | | 13 | | Adrenergic Antagonists | | Phase 4 | 1535 | | | | 14 | | Anti-Arrhythmia Agents | | Phase 4 | 2969 | | | | 15 | | Adrenergic beta-Antagonists | | Phase 4 | 1154 | | | | 16 | | Adrenergic beta-1 Receptor Antagonists | | Phase 4 | 350 | | | | 17 | | Prednisolone | approved, vet_approved | Phase 3 | 1153 | 50-24-8 | 5755 | (11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione .DELTA.1-Cortisol .DELTA.1-Dehydrocortisol .DELTA.1-Dehydrohydrocortisone .DELTA.1-Hydrocortisone .delta.-Cortef .delta.-Stab 1,2-Dehydrohydrocortisone 1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione 1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol 1-Dehydrocortisol 1-Dehydrohydrocortisone 3,20-dioxo-11beta,17alpha,21-Trihydroxy-1,4-pregnadiene 46656_FLUKA 46656_RIEDEL 50-24-8 58201-11-9 8056-11-9 AC-1773 AC1L1L2E Ak-Pred Ak-Tate Alphadrol Articulose-50 BPBio1_000164 BRD-K98039984-001-03-0 BRN 1354103 BSPBio_000148 Bio-0666 Bubbli-Pred C07369 CCRIS 980 CHEBI:8378 CHEMBL131 CID5755 CO-Hydeltra CPD000718761 Co-Hydeltra Codelcortone Cordrol Cortalone Cotogesic Cotolone D00472 D011239 DB00860 Decaprednil Decortin H Delcortol Delta F Delta(1)-dehydrohydrocortisone Delta-Cortef Delta-Cortef (TN) Delta-Ef-Cortelan Delta-Stab Delta-stab Deltacortenol Deltacortril Deltacortril Enteric Deltahydrocortisone Deltasolone Deltisilone Depo-Medrol Derpo PD Derpo Pd Dexa-Cortidelt Hostacortin H Dexa-Cortidelt hostacortin H Di Adreson F Di-Adreson F Di-Adreson-F Di-adreson F DiAdresonF Dicortol Donisolone Dydeltrone EINECS 200-021-7 Eazolin D Econopred Econopred Plus Erbacort Erbasona Estilsona Fernisolone Fernisolone P Fernisolone-P Flamasone HMS1568H10 HMS2090J05 HSDB 3385 Hostacortin H Hydeltra Hydeltra-Tba Hydeltrasol Hydeltrone Hydrodeltalone Hydrodeltisone Hydroretrocortin Hydroretrocortine I-Pred Inflamase Forte Inflamase Mild K 1557 Key-Pred Klismacort LMST02030179 LS-7669 Lentosone Lite Pred M-Predrol | MLS001304083 MLS002154250 MLS002207037 Medrol Medrol Acetate Metacortandralone Methylprednisolone Acetate Meti-Derm Meticortelone Metreton MolPort-002-507-147 NCGC00179649-01 NSC 9120 NSC9120 NSC9900 Neo-Delta-Cortef Nisolone Nor-Pred T.B.A. Ocu-Pred Ocu-Pred Forte Ophtho-Tate Orapred P0152_SIGMA P0637 P6004_SIGMA PRDL PRED-G Panafcortelone Paracortol Paracotol Pediapred Poly-Pred Precortalon Precortancyl Precortilon Precortisyl Pred Forte Pred Mild Predair Predair A Predair Forte Predalone 50 Predalone T.B.A. Predate Predate Tba Predate-50 Predcor-25 Predcor-50 Predcor-Tba Predisolone Sodium Phosphate Predne-Dome Prednelan Predni-Dome Prednicen Predniliderm Predniretard Prednis Prednisolona Prednisolona [INN-Spanish] Prednisolone (JP15/USP/INN) Prednisolone (anhydrous) Prednisolone Acetate Prednisolone Sodium Phosphate Prednisolone Tebutate Prednisolone [INN:BAN:JAN] Prednisolonum Prednisolonum [INN-Latin] Predonin Predonine Prelone Prenolone Prestwick0_000274 Prestwick1_000274 Prestwick2_000274 Prestwick3_000274 Prestwick_404 Rolisone S1737_Selleck SAM002264639 SMR000718761 SPBio_002367 Scherisolon Solone Steran Sterane Sterolone Supercortisol UNII-9PHQ9Y1OLM Ulacort Ultra Pred Ultracorten H Ultracortene H Ultracortene-H Ultracortene-Hydrogen Ultracortene-hydrogen ZINC03833821 component of Ataraxoid component of K-Predne-Dome delta(1)-Cortisol delta(1)-Dehydrocortisol delta(1)-Dehydrohydrocortisone delta(1)-Hydrocortisone delta(sup 1)-Cortisol delta(sup 1)-Dehydrocortisol delta(sup 1)-Dehydrohydrocortisone delta(sup 1)-Hydrocortisone delta-dehydrocortisol delta-dehydrohydrocortisone delta-hydrocortisone prednisolone | |
| | 18 | | Methylprednisolone | approved, vet_approved | Phase 3 | 1153 | 83-43-2 | 6741 | (6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one (6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione (6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione (6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione .DELTA.1-6.alpha.-Methylhydrocortisone 1-Dehydro-6alpha-methylhydrocortisone 1-dehydro-6alpha-Methylhydrocortisone 1-dehydro-6α-methylhydrocortisone 11-beta,17,21-Trihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione 11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione 11beta,17alpha,21-Trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione 11beta,17alpha,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione 121673-01-6 4-08-00-03498 (Beilstein Handbook Reference) 46436_FLUKA 46436_RIEDEL 570-35-4 6 Methylprednisolone 6-Methylprednisolone 6-alpha-Methylprednisolone 6.alpha.-Methylprednisolone 6923-42-8 6alpha-Methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione 6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione 6alpha-Methylprednisolone 6alpha-methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione 83-43-2 AC1L1N7A Artisone-Wyeth Artisone-wyeth BPBio1_000174 BRD-K35240538-001-03-1 BRN 2340300 BSPBio_000158 Besonia Bio-0658 CHEBI:6888 CHEMBL650 CID6741 CPD000058330 D00407 D008775 DB00959 Depo-Medrol (acetate) Dopomedrol EINECS 201-476-4 Esametone Firmacort HMS1568H20 HMS2090B13 HSDB 3127 LMST02030178 LS-118498 Lemod M0639_SIGMA M1665 MEPRDL MLS000028541 MLS001148159 MLS002207191 Medesone Medixon Medlone 21 | Medrate Medrol Medrol (TN) Medrol Adt Pak Medrol Dosepak Medrol adt pak Medrol dosepak Medrol, Solu-Medrol, Medrone, Methylprednisolone Medrone Mesopren Metastab Methyleneprednisolone Methylprednisolon Methylprednisolone Methylprednisolone (JP15/USP/INN) Methylprednisolone [USAN:INN:BAN:JAN] Methylprednisolone, 6-alpha Methylprednisolonum Methylprednisolonum [INN-Latin] Metilbetasone Metilprednisolona Metilprednisolona [INN-Spanish] Metilprednisolone Metilprednisolone [DCIT] Metilprednisolone [Dcit] Metipred Metrisone Metrocort Metysolon Moderin MolPort-002-528-554 NCGC00022735-03 NCI60_001657 NSC-19987 NSC19987 Nirypan Noretona Predni N Tablinen Prednol- L Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl- (8CI) Prestwick0_000279 Prestwick1_000279 Prestwick2_000279 Prestwick3_000279 Prestwick_622 Promacortine Reactenol S1733_Selleck SAM002589984 SMR000058330 SPBio_002377 Sieropresol Solomet Summicort Suprametil U 7532 UNII-X4W7ZR7023 Urbason Urbasone Wyacort ZINC03875560 delta(1)-6alpha-Methylhydrocortisone delta(sup 1)-6-alpha-Methylhydrocortisone methylprednisolone methylprenisolone |
| | 19 | | Prednisone | approved, vet_approved | Phase 3 | 1359 | 53-03-2 | 5865 | (1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione (8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione (8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione .delta. E .delta.(sup1)-Cortisone .delta.-Cortelan .delta.-Cortisone .delta.-Cortone .delta.-E .delta.1-Cortisone .delta.1-Dehydrocortisone .delta.sone 1,2-Dehydrocortisone 1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione 1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione 1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione 1-Cortisone 1-Dehydrocortisone 17,21-Dihydroxypregna-1,4-diene-3,11,20-trione 17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione 53-03-2 68-59-7 81552_FLUKA AC-11112 AC1L1LB2 AC1Q29EZ ACon0_000082 ACon1_000297 AI3-52939 Adasone Ancortone Apo-Prednisone Apo-prednisone BPBio1_000323 BRD-K85883481-001-04-2 BSPBio_000293 Betapar Bicortone Bio-0649 C07370 C21H26O5 CCRIS 2646 CHEBI:8382 CHEMBL635 CID5865 CPD001227202 Cartancyl Colisone Cortan Cortancyl Cortidelt Cotone DB00635 Dacorten Dacortin Decortancyl Decortin Decortisyl Dehydrocortisone Dekortin Delcortin Dellacort Dellacort A Delta Cortelan Delta E Delta E. Delta-Cortelan Delta-Dome Delta-cortelan Delta-cortisone Delta-cortone Delta-dome Deltacortene Deltacortisone Deltacortone Deltasone Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone Deltison Deltisona Deltisone Deltra Di-Adreson Diadreson EINECS 200-160-3 Econosone Encorton Encortone Enkortolon Enkorton Fernisone Fiasone HMS1568O15 HMS2090J13 HSDB 3168 Hostacortin In-Sone Incocortyl | Juvason Kortancyl LMST02030180 LS-1325 Liquid Pred Lisacort Lodotra MEGxm0_000443 MLS001061265 MLS001304073 MLS001335907 MLS001335908 MLS002154191 MLS002207083 Me-Korti Metacortandracin Meticorten Meticorten (Veterinary) Metrevet (Veterinary) MolPort-001-740-041 NCGC00090766-01 NCGC00090766-02 NCGC00090766-03 NCI-C04897 NCI60_000008 NSC 10023 NSC10023 Nisona Nizon Novoprednisone Nurison Orasone Origen Prednisone P1276 P6254_SIGMA PRD Panafcort Panasol Paracort Parmenison Pehacort Precort Predeltin Prednicen-M Prednicorm Prednicort Prednicot Prednidib Prednilonga Prednison Prednisona Prednisona [INN-Spanish] Prednisone Prednisone Intensol Prednisone [INN:BAN] Prednisonum Prednisonum [INN-Latin] Prednitone Prednizon Prednovister Presone Prestwick0_000077 Prestwick1_000077 Prestwick2_000077 Prestwick3_000077 Prestwick_405 Pronison Pronisone Rectodelt Retrocortine S1622_Selleck SAM002264641 SK-Prednisone SMR000718760 SMR001227202 SPBio_002214 Servisone Sone Sterapred Supercortil U 6020 UNII-VB0R961HZT Ultracorten Ultracortene WLN: L E5 B666 CV OV AHTTT&J A1 E1 FV1Q FQ Winpred Wojtab ZINC03875357 Zenadrid Zenadrid (veterinary) Zenadrid [veterinary] delta cortelan delta(sup 1)-Cortisone delta(sup 1)-Dehydrocortisone delta-1-Cortisone delta-1-Dehydrocortisone delta-Cortisone delta-Cortone | |
| | 20 | | Palbociclib | approved | Phase 2, Phase 3 | 113 | 571190-30-2 | 11431660, 5005498 | 2euf 571190-30-2 6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-[(5-PIPERAZIN-1-YLPYRIDIN-2-YL)AMINO]PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one AC1NS8RV CHEMBL189963 CID5330286 | EC-000.2350 Kinome_3823 Kinome_3824 LQQ PD 0332991 PD 332991, PD 0332991, PD0332991 PD-0332991 PD-332991 PD0332991 Palbociclib S1116_Selleck |
| | 21 | | nivolumab | approved | Phase 2, Phase 3, Phase 1 | 326 | 946414-94-4 | | | MDX-1106 ONO-4538 nivolumab |
| | 22 | | Docetaxel | approved, investigational, Approved May 1996 | Phase 2, Phase 3 | 1918 | 114977-28-5 | 148124, 9877265 | (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-[[(1,1-dimethylethoxy)carbonyl]amino]-a-hydroxybenzenepropanoate (2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate 01885_FLUKA 114977-28-5 4-(Acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate 4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate AC-383 AC1L3WHJ ANX-514 BIND-014 C11231 CHEBI:4672 CHEMBL92 CID148124 D07866 DB01248 Docetaxel Docetaxel (INN) Docetaxel anhydrous Docetaxel, Trihydrate EmDOC | HMS2089K08 InChI=1/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,5 MolPort-003-847-005 N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol N-debenzoyl-N-Boc-10-deacetyl taxol NSC-628503 PSMA-targeted docetaxel nanoparticle RP-56976 SDP-014 TXL Taxotere Taxotere (TN) Taxotere(R) XRP-6976L docetaxel docetaxel 114977-28-5 nchembio.188-comp8 nchembio.2007.34-comp7 nchembio.573-comp11 nchembio853-comp8 |
| | 23 | | Protein Kinase Inhibitors | | Phase 2, Phase 3, Phase 1 | 3612 | | | | 24 | | Prednisolone acetate | | Phase 3 | 1153 | | | | 25 | | Prednisolone hemisuccinate | | Phase 3 | 1153 | | | | 26 | | Prednisolone phosphate | | Phase 3 | 1153 | | | | 27 | | Protective Agents | | Phase 3 | 7190 | | | | 28 | | Antibodies, Monoclonal | | Phase 2, Phase 3, Phase 1 | 3795 | | | | 29 | | Pharmaceutical Solutions | | Phase 3 | 7793 | | | | 30 | | Neuroprotective Agents | | Phase 3 | 1672 | | | | 31 | | Antibodies | | Phase 3, Phase 2, Phase 1 | 6045 | | | | 32 | | glucocorticoids | | Phase 3, Phase 1, Phase 2 | 4920 | | | | 33 | | Gastrointestinal Agents | | Phase 3, Phase 1, Phase 2 | 8109 | | | | 34 | | Antiemetics | | Phase 3, Phase 1, Phase 2 | 3888 | | | | 35 | | Antineoplastic Agents, Hormonal | | Phase 3, Phase 1, Phase 2 | 5407 | | | | 36 | | Hormone Antagonists | | Phase 3, Phase 1, Phase 2 | 12778 | | | | 37 | | Hormones | | Phase 3, Phase 1, Phase 2 | 13979 | | | | 38 | | Methylprednisolone acetate | | Phase 3 | 1153 | | | | 39 | | Methylprednisolone Hemisuccinate | | Phase 3 | 1153 | | | | 40 | | Immunoglobulins | | Phase 3, Phase 2, Phase 1 | 6045 | | | | 41 | | Immunoglobulin G | | Phase 3, Phase 2, Phase 1 | 265 | | | | 42 | | Hormones, Hormone Substitutes, and Hormone Antagonists | | Phase 3, Phase 1, Phase 2 | 12767 | | | | 43 | | Anti-Inflammatory Agents | | Phase 3, Phase 1, Phase 2 | 10355 | | | | 44 | | Erlotinib Hydrochloride | | Phase 2, Phase 3 | 798 | 183319-69-9 | 176871 | | | 45 | | Antimitotic Agents | | Phase 2, Phase 3 | 5498 | | | | 46 | | rituximab | approved | Phase 1, Phase 2 | 1654 | 174722-31-7 | 10201696 | AntiCD20 IDEC-102 IDEC-C2B8 | Ig gamma-1 chain C region MabThera Mabthera Rituxan rituximab |
| | 47 | | Dasatinib | approved, investigational | Phase 1, Phase 2 | 281 | 302962-49-8 | 3062316 | (18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide 1N1 2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide 302962-49-8 AC1MI3ET AC1Q2P0C AmbotzLS-1203 Anhydrous dasatinib BCB03_000715 BMS 354825 BMS dasatinib BMS-354825 BMS-354825, Sprycel, BMS354825, Dasatinib BMS354825 C488369 CHEBI:49375 CHEMBL1421 CID3062316 D03658 DB01254 Dasatinib Dasatinib (USAN) Dasatinib (anh.) Dasatinib [USAN] Dasatinib anhydrous Dasatinib, BMS 354825 Dasatinibum EC-000.2122 | EN002710 FT-0084503 I14-1972 Kinome_3650 LS-186641 LS-187028 LS-187773 MolPort-003-846-143 N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, monohydrate N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide NCGC00181129-01 NSC-732517 NSC732517 S1021_Selleck SPRYCEL (TN) Sprycel Spyrcel UNII-X78UG0A0RN anh. dasatinib dasatinib dasatinib (anhydrous) dasatinibum nchembio.117-comp11 nchembio.162-comp4 nchembio.332-comp1 | |
| | 48 | | Melphalan | approved | Phase 1, Phase 2 | 712 | 148-82-3 | 4053, 460612 | (2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid (2s)-2-amino-3-(4-[bis(2-chloroethyl)amino]phenyl)propanoic acid 148-82-3 3-(P-(Bis(2-chloroethyl)amino)phenyl)-L-alanine 3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine 3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine 3-P-(Di(2-chloroethyl)amino)-phenyl-L-alanine 3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine 3025 C.B. 3025 c.b 3223-07-2 4-(Bis(2-chloroethyl)amino)-L-phenylalanine 4-14-00-01689 (Beilstein Handbook Reference) 4-[Bis(2-chloroethyl)amino]-L-phenylalanine 4-[Bis-(2-chloroethyl)amino]-L-phenylalanine AC1LA2OE ALKERAN (TN) AY3360000 Alanine Nitrogen Mustard Alkeran AmbotzHAA1563 At-290 BIDD:GT0044 BRD-K87827419-001-02-8 BRN 2816456 BSPBio_002407 C13H18Cl2N2O2 CB 3025 CB-3025 CCRIS 374 CHEBI:165415 CHEBI:28876 CHEMBL852 CID460612 D00369 DivK1c_000653 EINECS 205-726-3 HMS2090B09 HMS2091B16 HMS502A15 HSDB 3234 IDI1_000653 KBio1_000653 KBio2_000877 KBio2_003445 KBio2_006013 KBio3_001627 KBioGR_001284 KBioSS_000877 L-3-(P-(Bis(2-chloroethyl)amino)phenyl)alanine L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine L-3-(para-(Bis(2-chloroethyl)amino)phenyl)alanine L-PAM L-Phenylalanine mustard L-Sarcolysin L-Sarcolysine L-Sarkolysin LS-15868 LS-865 | Levofalan Levofolan Levopholan M2011_SIGMA MELPHALAN (SEE ALSO TRANSGENIC MODEL EVALUATION (MELPHALAN)) MLS001333666 MLS002153368 Melfalan Melfalano Melfalano [INN-Spanish] Melphalan (JP15/USP/INN) Melphalan [USAN:INN:BAN:JAN] Melphalanum Melphalanum [INN-Latin] Mephalan MolPort-003-665-535 NCGC00090757-01 NCGC00090757-02 NCGC00090757-03 NCI-C04853 NINDS_000653 NIOSH/AY3360000 NSC 241286 NSC 8806 NSC-8806 NSC241286 NSC8806 P-Di-(2-chloroethyl)amino-L-phenylalanine P-L-Sarcolysin P-N-Bis(2-chloroethyl)amino-L-phenylalanine Phenylalanine mustard Phenylalanine nitrogen mustard Prestwick_1006 RCRA waste no. U150 Rcra waste number U150 SK-15673 SMP2_000174 SMR000058720 SPBio_000287 SPECTRUM1500382 Sarcolysine Sarkolysin Spectrum2_000074 Spectrum3_000684 Spectrum4_000882 Spectrum5_001601 Spectrum_000397 TL8001065 TRANSGENIC LEP (MELPHALAN) (SEE ALSO MELPHALAN) TRANSGENIC MODEL EVALUATION (MELPHALAN) UNII-Q41OR9510P melphalan p-Bis(beta-chloroethyl)aminophenylalanine p-Di-(2-chloroethyl)amino-L-phenylalanine p-L-Sarcolysin p-L-sarcolysine p-N,N-bis(2-chloroethyl)amino-L-phenylalanine p-N-Bis(2-chloroethyl)amino-L-phenylalanine p-N-Di(chloroethyl)aminophenylalanine p-N-di(chloroethyl)aminophenylala nine phenylalanine nitrogen mu stard |
| | 49 | | Mechlorethamine | approved | Phase 2 | 377 | 51-75-2 | 4033 | .Beta.,.beta.'-Dichlorodiethyl-N-methylamine 1, 5-Dichloro-3-methyl-3-azapentane hydrochloride 126-85-2 (N-oxide) 2,2'-Dichloro-N-me 2,2'-Dichloro-N-methyldiethylamine 2,2'-Dichlorodiethyl-methylamine 2,2'-dichloro-N-methyldiethylamine 2-Chloro-N-(2-chloroethyl)-N-methylethanamine 302-70-5 (N-oxide, hydrochloride) 51-75-2 55-86-7 (HYDROCHLORIDE) AC1L1H9H Antimit BRN 0605323 BSPBio_001947 Bis(2-chloroethyl)methylamine Bis(beta-chloroethyl) methylamine Bis(beta-chloroethyl)methylamine C07115 C5H11Cl2N CCRIS 447 CHEBI:28925 CHEMBL427 CID4033 Carolysine Caryolysin Caryolysine Chloramine (the nitrogen mustard) Chlorethazine Chlormethine Chlormethine (INN) Chlormethine [INN:BAN] Chlormethinum [INN-Latin] Cloramin Clormetina Clormetina [INN-Spanish] D07671 DB00888 Di(2-chloroethyl)methylamine Dichlor amine Dichloren DivK1c_000759 EINECS 200-120-5 ENT-25294 Embechine Embichin HMS1920J15 HMS2091B04 HMS502F21 HN-2 HN2 HSDB 5083 I14-8708 IBS-L0033631 IDI1_000759 KBio1_000759 KBio2_001369 KBio2_003937 KBio2_006505 KBio3_001447 | KBioGR_001448 KBioSS_001369 LS-7559 MBA Me chloroethamine Mebichloramine Mechlorethamine Mechlorethanamine Mechloroethamine Mecloretamina Mecloretamina [Italian] Methylbis(2-chloroethyl)amine Methylbis(beta-chloroethyl)amine Methyldi(2-chloroethyl)amine Mitoxine (*Hydrochloride*) MolPort-001-785-592 Mustargen Mustine Mustine note Mutagen N,N-Bis(2-chloroethyl)-N-methylamine N,N-Bis(2-chloroethyl)methylamine N,N-Di(chloroethyl)methylamine N-Lost N-Methyl lost N-Methyl-2,2'-dichlorodiethylamine N-Methyl-bis(2-chloroethyl)amine N-Methyl-bis(beta-chloroethyl)amine N-Methyl-bis-chloraethylamin N-Methyl-bis-chloraethylamin [German] N-Methyl-lost N-Methyl-lost [German] N-methyl-bis(2-chloroethyl)amine NCGC00091835-02 NCGC00091835-03 NCGC00091835-04 NCGC00091835-05 NCI60_041682 NINDS_000759 NSC762 Nitol (*Hydrochloride*) Nitrogen mustard Nitrogen mustard (HN-2) Nitrogranulogen SPBio_000496 SPECTRUM1500375 Spectrum2_000448 Spectrum3_000484 Spectrum4_000924 Spectrum5_001702 Spectrum_000889 Stickstofflost (*Hydrochloride*) Stickstofflost (ebewe) T 1024 T-1024 TL 146 UNII-50D9XSG0VR beta,Beta'-dichlorodiethyl-N-methylamine beta,beta'-Dichlorodiethyl-N-methylamine mechlorethamine thyldiethylamine β,β'-dichlorodiethyl-N-methylamine |
| | 50 | | Lenalidomide | approved | Phase 1, Phase 2 | 718 | 191732-72-6 | 216326 | 1-oxo-2-(2,6-Dioxopiperidin-3-yl)-4-aminoisoindoline 191732-72-6 3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione 3-(7-Amino-3-oxo-1H-isoindol-2-yl)-piperidine-2,6-dione 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione 346670-73-3 443912-14-9 AC-914 AC1L50II AKOS005146276 ALBB-015321 Bio-0168 C467567 CC 5013 CC-5013 CC-5013, Revlimid, Lenalidomide CC5013 CDC 501 CDC-501 CDC-5013 CHEMBL848 CID216326 Celgene brand of lenalidomide D04687 | DB00480 EC-000.2340 ENMD-0997 I06-0831 IMID-1 IMID-5013 IMiD3 IMiD3 cpd IMid-1 LS-184040 Lenalidomide Lenalidomide (USAN/INN) Lenalidomide [USAN] MolPort-003-848-370 NCGC00167491-01 NSC747972 Revamid Revimid Revlimid Revlimid (Celgene) Revlimid (TN) S1029_Selleck STK639603 Thalidomide analog CC-5013 UNII-F0P408N6V4 lenalidomide | |
|
Interventional clinical trials: (show top 50)
(show all 55)
| id | Name | Status | NCT ID | Phase |
|---|
| 1 | Effects of Exercise Training on Systemic Inflammation an Muscle Repair According to the Obstructive Chronic Pulmonary Disease (COPD) Phenotype | Unknown status | NCT01431625 | Phase 4 | | 2 | Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart | Completed | NCT01798992 | Phase 4 | | 3 | Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma | Completed | NCT01691508 | Phase 3 | | 4 | Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control | Completed | NCT02281318 | Phase 3 | | 5 | Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer | Recruiting | NCT02154490 | Phase 2, Phase 3 | | 6 | Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients | Recruiting | NCT02555371 | Phase 3 | | 7 | Efficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic Obstructive Pulmonary Disease (COPD) | Active, not recruiting | NCT02105961 | Phase 3 | | 8 | Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients | Active, not recruiting | NCT02105948 | Phase 3 | | 9 | A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects | Active, not recruiting | NCT02135692 | Phase 3 | | 10 | A Study of Dasatinib and Rituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia | Unknown status | NCT00949988 | Phase 1, Phase 2 | | 11 | A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma | Completed | NCT00464178 | Phase 2 | | 12 | Everolimus in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma | Completed | NCT00516412 | Phase 2 | | 13 | Lenalidomide in Combination With Melphalan and Dexamethasone in Newly-diagnosed Light-chain (AL)-Amyloidosis | Completed | NCT00621400 | Phase 1, Phase 2 | | 14 | Assessing Free Immunoglobulin Light Chains in Patients With Myeloma | Completed | NCT00301275 | Phase 2 | | 15 | Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL) | Completed | NCT01520922 | Phase 2 | | 16 | Natalizumab Treatment of Progressive Multiple Sclerosis | Completed | NCT01077466 | Phase 2 | | 17 | CFAR Study in Patients With Chronic Lymphocytic Leukemia | Completed | NCT00525603 | Phase 2 | | 18 | Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | Completed | NCT01082939 | Phase 2 | | 19 | HORMA: Hormonal Regulators of Muscle and Metabolism in Aging | Completed | NCT00183040 | Phase 2 | | 20 | Immuno-modulation in Amyotrophic Lateral Sclerosis- a Phase II Study of Safety and Activity of Low Dose Interleukin-2 | Completed | NCT02059759 | Phase 2 | | 21 | Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma | Recruiting | NCT02794883 | Phase 2 | | 22 | SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer | Recruiting | NCT02581787 | Phase 1, Phase 2 | | 23 | Exercise For Sub-acute Stroke Patients in Jamaica | Recruiting | NCT01392391 | Phase 2 | | 24 | S1400A Lung-Map: MEDI4736 as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers | Active, not recruiting | NCT02766335 | Phase 2 | | 25 | MABp1 IN HIDRADENITIS SUPPURATIVA REFRACTORY TO ADALIMUMAB | Active, not recruiting | NCT02643654 | Phase 2 | | 26 | Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | Not yet recruiting | NCT02966587 | Phase 2 | | 27 | Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma | Not yet recruiting | NCT03011814 | Phase 1, Phase 2 | | 28 | Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRAC2 Mutation | Not yet recruiting | NCT02953457 | Phase 1, Phase 2 | | 29 | Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer | Not yet recruiting | NCT02888743 | Phase 2 | | 30 | Tocilizumab for Chronic Graft-versus-Host Disease Treatment | Withdrawn | NCT02174263 | Phase 2 | | 31 | Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis | Recruiting | NCT02871323 | Phase 1 | | 32 | JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Recruiting | NCT02706405 | Phase 1 | | 33 | Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract | Recruiting | NCT02925533 | Phase 1 | | 34 | Phase I Study of Investigational Medicinal Products in Children With Relapsed/Refractory Neuroblastoma | Not yet recruiting | NCT02914405 | Phase 1 | | 35 | Study of Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneration | Withdrawn | NCT00726466 | Phase 1 | | 36 | Prospective Collection of Biological Data of Prognostic Relevance in Patients With B-Cell Chronic Lymphocytic Leukemia | Unknown status | NCT00917540 | | | 37 | Genetic Test in Detecting Minimal Residual Disease in Samples From Younger Patients Registered on the COG-AALL08B1 Trial | Completed | NCT01629745 | | | 38 | Genetic Test To Identify Previously Undetectable Minimal Residual Disease in Cell Samples From Younger Patients With Acute Lymphoblastic Leukemia | Completed | NCT01533168 | | | 39 | Polymorphism of the IgH Locus Regulatory Region as a Prognostic Factor During Immune Pathologies. | Completed | NCT01715623 | | | 40 | The Relationship Between Arsenic Methylation Capability and Blood Metals in Children With Developmental Delays | Completed | NCT02523989 | | | 41 | A Study to Evaluate the Performance of a Diagnostic Test in ALS | Recruiting | NCT02759913 | | | 42 | Mutations in Genes Associated With Pentalogy of Cantrell | Recruiting | NCT00083499 | | | 43 | Screening for the Transthyretin-Related Familial Amyloidotic Small Fiber Polyneuropathy | Recruiting | NCT01705626 | | | 44 | Evaluation of the Axonemal Dynein Heavy Chain 5 and Creatine Kinase Concentration in Cervical Fluid for Early Detection of the Ectopic Pregnancy | Recruiting | NCT02995356 | | | 45 | Utility of Plasma Circulating Tumor DNA (ctDNA) in Asymptomatic Subjects for the Detection of Neoplastic Disease | Recruiting | NCT02612350 | | | 46 | Study of Decreasing Kinetics of the Leptospiremia During Antibiotic Treatment of Leptospirosis in Martinique | Recruiting | NCT02000635 | | | 47 | Heavy Light Chain in Chronic Lymphocytic Leukemia | Recruiting | NCT02377869 | | | 48 | Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis | Active, not recruiting | NCT01383759 | | | 49 | The Effects of Exercise Training on Shoulder Neuromuscular Control | Active, not recruiting | NCT02164305 | | | 50 | Molecular Features Underlying Racial Differences in Survival of Taiwanese Chronic Lymphocytic Leukemia Patients | Enrolling by invitation | NCT02553304 | |
|
